{"content":"<li class=\"n-box-item date-title\" data-end=\"1507348799\" data-start=\"1507262400\" data-txt=\"Monday, December 23, 2019\">Friday, October  6, 2017</li><li class=\"n-box-item sa-box-item\" data-id=\"3299867\" data-ts=\"1507328629\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BGC\" target=\"_blank\">BGC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299867-general-cableplus-5-on-reports-of-possible-takeover-bid\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">General Cable +5% on reports of possible takeover bid</a></h4><ul>     <li>General Cable (NYSE:<a href='https://seekingalpha.com/symbol/BGC' title='General Cable Corporation'>BGC</a>) popped 5% in today's trade following a Reuters report that the cable manufacturer had <a href=\"https://www.reuters.com/article/us-general-cable-m-a-prysmian-nexans-nkt/general-cable-receives-bids-from-european-rivals-prysmian-nexans-and-nkt-sources-idUSKBN1CB2IC\" target=\"_blank\">received tentative takeover offers</a> from European rivals Prysmian (<a href='https://seekingalpha.com/symbol/PRYMF' title='Prysmian S.P.A.'>OTCPK:PRYMF</a>), Nexans (<a href='https://seekingalpha.com/symbol/NEXNY' title='NEXANS UNSP/ADR'>OTC:NEXNY</a>) and NKT (<a href='https://seekingalpha.com/symbol/NRKBF' title='NKT Holding A/S'>OTC:NRKBF</a>); shares are up another 2% after-hours.</li><li>U.S. wire maker Southwire, which has bought some assets from BGC in past years, also could be part of the bidding field, according to t he report.</li><li>Kentucky-based BGC hired J.P. Morgan in July to kick off a strategic review and identify a possible  merger partner.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3299867\" data-linked=\"General Cable +5% on reports of possible takeover bid\" data-tweet=\"$BGC $BGC $PRYMF - General Cable +5% on reports of possible takeover bid https://seekingalpha.com/news/3299867-general-cableplus-5-on-reports-of-possible-takeover-bid?source=tweet\" data-url=\"https://seekingalpha.com/news/3299867-general-cableplus-5-on-reports-of-possible-takeover-bid\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:23 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299865\" data-ts=\"1507328006\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CDNA\" target=\"_blank\">CDNA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299865-caredxplus-2_5-major-holder-gagnon-buys-10642-shares\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CareDx +2.5% as major holder Gagnon buys 10,642 shares</a></h4><ul>   <li>Neil Gagnon, a major shareholder in CareDx (<a href=\"http://seekingalpha.com/symbol/CDNA\" target=\"_blank\">CDNA</a> <font color='red'>-3.4%</font>), has <a href=\"https://seekingalpha.com/filing/3722954\" target=\"_blank\">bought 10,642 shares</a>, according to a Form 4 filed with the SEC.</li>    <li>Shares are <font color='green'>up 2.5%</font> after hours.</li>    <li>He directly bought 9,364 shares, bringing beneficial ownership to 928,768 shares. He also indirectly bought another 1,278 shares as a trustee of Gagnon Securities LLC Profit Sharing Plan.</li>    <li>All transactions were at $4/share; the stock closed at $5.62 today and is seeing $5.76 quotes postmarket.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3299865\" data-linked=\"CareDx +2.5% as major holder Gagnon buys 10,642 shares\" data-tweet=\"$CDNA - CareDx +2.5% as major holder Gagnon buys 10,642 shares https://seekingalpha.com/news/3299865-caredxplus-2_5-major-holder-gagnon-buys-10642-shares?source=tweet\" data-url=\"https://seekingalpha.com/news/3299865-caredxplus-2_5-major-holder-gagnon-buys-10642-shares\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:13 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299860\" data-ts=\"1507326218\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NYT\" target=\"_blank\">NYT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299860-new-york-timesminus-1_8-weinstein-threatens-suit-over-expose\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">New York Times -1.8% as Weinstein threatens suit over expose</a></h4><ul>    <li>The New York Times Co. (NYSE:<a href='https://seekingalpha.com/symbol/NYT' title='New York Times Co.'>NYT</a>) finished <font color='red'>1.8% lower</font> today amid threats of a lawsuit from movie mogul Harvey Weinstein, the subject of an expose detailing decades of allegations of sexual harassment.</li>    <li>Along with his brother Bob, Harvey Weinstein co-founded Miramax Films, and co-founded mini-major studio the Weinstein Company in 2005.</li>    <li>The <i>New York Times</i> story <a href=\"https://www.nytimes.com/2017/10/05/us/harvey-weinstein-harassment-allegations.html\" target=\"_blank\">reports decades of payoffs</a> given to Weinstein's accusers. Today, Weinstein planned a leave of absence as the board at the Weinstein Co. initiated an investigation.</li>    <li>Weinstein hasn't filed a suit yet (and libel cases are notoriously difficult to win), but his attorney says <a href=\"http://www.hollywoodreporter.com/thr-esq/harvey-weinstein-lawsuit-new-york-times-is-being-prepared-says-his-attorney-1046170\" target=\"_blank\">one is being prepared</a>. That news came alongside Weinstein's <a href=\"https://www.nytimes.com/interactive/2017/10/05/us/statement-from-harvey-weinstein.html\" target=\"_blank\">statement</a> that he framed as an apology for conduct.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3299860\" data-linked=\"New York Times -1.8% as Weinstein threatens suit over expose\" data-tweet=\"$NYT - New York Times -1.8% as Weinstein threatens suit over expose https://seekingalpha.com/news/3299860-new-york-timesminus-1_8-weinstein-threatens-suit-over-expose?source=tweet\" data-url=\"https://seekingalpha.com/news/3299860-new-york-timesminus-1_8-weinstein-threatens-suit-over-expose\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:43 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299858\" data-ts=\"1507325707\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299858-after-hours-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">After Hours Gainers / Losers</a></h4><ul>     <li><b>Top gainers, as of 5.25 p.m.:</b> ITEK <font color='green'>+3.8%</font>. <a href='https://seekingalpha.com/symbol/CDNA' title='CareDx'>CDNA</a> <font color='green'>+2.49%</font>. <a href='https://seekingalpha.com/symbol/FLXN' title='Flexion Therapeutics, Inc.'>FLXN</a> <font color='green'>+1.9%</font>. <a href='https://seekingalpha.com/symbol/ACRX' title='AcelRx Pharmaceuticals, Inc.'>ACRX</a> <font color='green'>+1.9%</font>. <a href='https://seekingalpha.com/symbol/SECO' title='Secoo Holding'>SECO</a> <font color='green'>+1.9%</font>.</li>     <li><b>Top losers, as of 5.25p.m.:</b> <a href='https://seekingalpha.com/symbol/MDT' title='Medtronic plc'>MDT</a> <font color='red'>-1.9%</font>. <a href='https://seekingalpha.com/symbol/YRD' title='Yirendai LTD.'>YRD</a> <font color='red'>-1.6%</font>. <a href='https://seekingalpha.com/symbol/KL' title='Kirkland Lake Gold Ltd.'>KL</a> <font color='red'>-1.5%</font>. <a href='https://seekingalpha.com/symbol/APVO' title='Aptevo Therapeutics Inc.'>APVO</a> <font color='red'>-1.48%</font>. <a href='https://seekingalpha.com/symbol/MFA' title='MFA Financial, Inc.'>MFA</a> <font color='red'>-1.4%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3299858\" data-linked=\"After Hours Gainers / Losers\" data-tweet=\"$RCKT $CDNA $FLXN - After Hours Gainers / Losers https://seekingalpha.com/news/3299858-after-hours-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3299858-after-hours-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:35 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299843\" data-ts=\"1507322536\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SFTBY\" target=\"_blank\">SFTBY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299843-bloomberg-senate-dems-press-for-government-review-of-sprint-t-mobile\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Bloomberg: Senate Dems press for government review of Sprint/T-Mobile</a></h4><ul>    <li>With a merger between Sprint (<a href=\"http://seekingalpha.com/symbol/S\" target=\"_blank\">S</a> <font color='red'>-1.8%</font>) and T-Mobile (<a href=\"http://seekingalpha.com/symbol/TMUS\" target=\"_blank\">TMUS</a> <font color='green'>+1.5%</font>) gathering steam for a <a href=\"https://seekingalpha.com/news/3299778-bloomberg-sprint-t-mobile-final-approach-deal-month\" target=\"_blank\">possible firm announcement alongside earnings</a>, Senate Democrats are pressing the Trump administration to start reviewing the deal for consumer harm ahead of any announcement, Bloomberg reports.</li>    <li>A letter spearheaded by Sen. Amy Klobuchar (to the Justice Department's new antitrust chief Makan Delrahim and to FCC Chairman Ajit Pai) says the combination \"could raise significant antitrust issues and could harm consumers\" and urges the two to start looking into the deal.</li>    <li>Klobuchar is the top Democrat for antitrust issues on the Senate Judiciary Committee.</li>    <li>The carriers' parent firms today: <a href='https://seekingalpha.com/symbol/SFTBY' title='SoftBank Group ADR'>OTCPK:SFTBY</a> <font color='green'>+0.2%</font>; <a href='https://seekingalpha.com/symbol/DTEGY' title='Deutsche Telekom AG ADR'>OTCQX:DTEGY</a> <font color='green'>+0.3%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3299843\" data-linked=\"Bloomberg: Senate Dems press for government review of Sprint/T-Mobile\" data-tweet=\"$SFTBY $SFTBY $DTEGY - Bloomberg: Senate Dems press for government review of Sprint/T-Mobile https://seekingalpha.com/news/3299843-bloomberg-senate-dems-press-for-government-review-of-sprint-t-mobile?source=tweet\" data-url=\"https://seekingalpha.com/news/3299843-bloomberg-senate-dems-press-for-government-review-of-sprint-t-mobile\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:42 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>44&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299839\" data-ts=\"1507322206\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299839-weekly-etf-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Weekly ETF Gainers / Losers</a></h4><ul>     <li><b>Top gainers:</b> <a href='https://seekingalpha.com/symbol/REMX' title='VanEck Vectors Rare Earth/Strategic Metals ETF'>REMX</a> <font color='green'>+5.2%</font>. <a href='https://seekingalpha.com/symbol/FXI' title='iShares China Large-Cap ETF'>FXI</a> <font color='green'>+4.0%</font>. <a href='https://seekingalpha.com/symbol/BRF' title='VanEck Vectors Brazil Small-Cap ETF'>BRF</a> <font color='green'>+3.3%</font>. <a href='https://seekingalpha.com/symbol/GDXJ' title='VanEck Vectors Junior Gold Miners ETF'>GDXJ</a> <font color='green'>+3.0%</font>. <a href='https://seekingalpha.com/symbol/GDX' title='VanEck Vectors Gold Miners ETF'>GDX</a> <font color='green'>+2.7%</font>.</li><li><b>Top losers:</b> <a href='https://seekingalpha.com/symbol/OIL' title='iPath S&P Crude Oil Total Return Index ETN'>OIL</a> <font color='red'>-5.6%</font>. <a href='https://seekingalpha.com/symbol/VXX' title='iPath S&P 500 VIX Short-Term Futures ETN'>VXX</a> <font color='red'>-5.4%</font>. <a href='https://seekingalpha.com/symbol/UNG' title='The United States Natural Gas ETF, LP'>UNG</a> <font color='red'>-4.9%</font>. <a href='https://seekingalpha.com/symbol/USO' title='The United States Oil ETF, LP'>USO</a> <font color='red'>-4.4%</font>. <a href='https://seekingalpha.com/symbol/GAZ' title='iPath DJ-UBS Natural Gas Total Return Sub-Index ETN'>GAZ</a> <font color='red'>-3.7%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3299839\" data-linked=\"Weekly ETF Gainers / Losers\" data-tweet=\"$REMX $FXI $BRF - Weekly ETF Gainers / Losers https://seekingalpha.com/news/3299839-weekly-etf-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3299839-weekly-etf-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:36 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299829\" data-ts=\"1507319507\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FLXN\" target=\"_blank\">FLXN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299829-flexion-pegs-wholesale-price-of-zilretta-570-per-dose-shares-up-7-on-fda-ok\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Flexion pegs wholesale price of Zilretta at $570 per dose; shares up 7% on FDA OK</a></h4><ul><li>Flexion Therapeutics (<a href='https://seekingalpha.com/symbol/FLXN' title='Flexion Therapeutics, Inc.'>FLXN</a> <font color='green'>+7.2%</font>) <a href=\"https://www.sec.gov/Archives/edgar/data/1419600/000119312517305740/d434786d8k.htm\" target=\"_blank\">expects</a> the wholesale acquisition price of just-approved Zilretta (triamcinolone acetonide extended-release injectable suspension) to be $570 per dose. Commercial launch should commence in mid-November.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3299824-fda-oks-flexions-zilretta-osteoarthritis-knee-pain\" target=\"_blank\">FDA OKs Flexion's Zilretta for osteoarthritis knee pain</a> (Oct. 6)</li></ul><div class=\"tiny-share-widget\" data-id=\"3299829\" data-linked=\"Flexion pegs wholesale price of Zilretta at $570 per dose; shares up 7% on FDA OK\" data-tweet=\"$FLXN - Flexion pegs wholesale price of Zilretta at $570 per dose; shares up 7% on FDA OK https://seekingalpha.com/news/3299829-flexion-pegs-wholesale-price-of-zilretta-570-per-dose-shares-up-7-on-fda-ok?source=tweet\" data-url=\"https://seekingalpha.com/news/3299829-flexion-pegs-wholesale-price-of-zilretta-570-per-dose-shares-up-7-on-fda-ok\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:51 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>14&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299824\" data-ts=\"1507317079\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FLXN\" target=\"_blank\">FLXN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299824-fda-oks-flexions-zilretta-for-osteoarthritis-knee-pain\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA OKs Flexion&#39;s Zilretta for osteoarthritis knee pain</a></h4><ul><li>The FDA <a href=\"https://seekingalpha.com/pr/16962166-flexion-therapeutics-announces-fda-approval-zilretta-triamcinolone-acetonide-extended-release\" target=\"_blank\">approves</a> Flexion Therapeutics' (<a href='https://seekingalpha.com/symbol/FLXN' title='Flexion Therapeutics, Inc.'>FLXN</a> <font color='red'>-4.3%</font>) Zilretta (triamcinolone acetonide extended-release injectable suspension) for the treatment of knee pain due to osteoarthritis. The non-opioid medication is administered via an injection into the knee joint and provides pain relief for up to 12 weeks.</li><li>Zilretta should be available by prescription by the end of the month.</li><li>Management will host a conference call on Monday, October 9 at 8:00 am ET to discuss the approval and launch plans.</li><li>Shares are due to resume trading in about 10 minutes.</li></ul><div class=\"tiny-share-widget\" data-id=\"3299824\" data-linked=\"FDA OKs Flexion&#39;s Zilretta for osteoarthritis knee pain\" data-tweet=\"$FLXN - FDA OKs Flexion&#39;s Zilretta for osteoarthritis knee pain https://seekingalpha.com/news/3299824-fda-oks-flexions-zilretta-for-osteoarthritis-knee-pain?source=tweet\" data-url=\"https://seekingalpha.com/news/3299824-fda-oks-flexions-zilretta-for-osteoarthritis-knee-pain\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:11 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299822\" data-ts=\"1507316511\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CNET\" target=\"_blank\">CNET</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299822-chinanet-online-jumps-23-on-heavy-volume\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">ChinaNet Online jumps 23% on heavy volume</a></h4><ul>   <li>Ad platform company ChinaNet Online Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/CNET' title='ChinaNet Online Holdings, Inc.'>CNET</a>) is seeing highly unusual action today, <font color='green'>up 23.1%</font> on more than 140 times usual volume.</li>    <li>A small block of a few hundred shares crossed the tape at $1.99 today, 91% above yesterday's close.</li>    <li>At last report the stock's short percent of float was low, at 0.92%.</li>    <li>Shares are now <font color='green'>up 35%</font> since Aug. 30.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3299822\" data-linked=\"ChinaNet Online jumps 23% on heavy volume\" data-tweet=\"$CNET - ChinaNet Online jumps 23% on heavy volume https://seekingalpha.com/news/3299822-chinanet-online-jumps-23-on-heavy-volume?source=tweet\" data-url=\"https://seekingalpha.com/news/3299822-chinanet-online-jumps-23-on-heavy-volume\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:01 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299820\" data-ts=\"1507316167\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299820-technology-top-gainers-losers-of-2-55-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Technology - Top Gainers / Losers as of 2:55 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/SNCR' title='Synchronoss Technologies, Inc.'>SNCR</a> <font color='green'>+30%</font>. <a href='https://seekingalpha.com/symbol/KONE' title='Kingtone Wirelessinfo Solution Holding Ltd'>KONE</a> <font color='green'>+21%</font>. <a href='https://seekingalpha.com/symbol/MTBC' title='Medical Transcription Billing'>MTBC</a> <font color='green'>+14%</font>. <a href='https://seekingalpha.com/symbol/EGAN' title='eGain Communications Corp.'>EGAN</a> <font color='green'>+12%</font>. <a href='https://seekingalpha.com/symbol/SIFY' title='Sify Technologies Limited'>SIFY</a> <font color='green'>+11%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/NETE' title='Net Element International, Inc.'>NETE</a> <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/MRAM' title='Everspin Technologies'>MRAM</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/LOV' title='Spark Networks, Inc'>LOV</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/INAP' title='Internap Network Services Corporation'>INAP</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/NH' title='NantHealth'>NH</a> <font color='red'>-8%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3299820\" data-linked=\"Technology - Top Gainers / Losers as of 2:55 pm\" data-tweet=\"$SNCR $KONE $MTBC - Technology - Top Gainers / Losers as of 2:55 pm https://seekingalpha.com/news/3299820-technology-top-gainers-losers-of-2-55-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3299820-technology-top-gainers-losers-of-2-55-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:56 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299817\" data-ts=\"1507315358\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GPRO\" target=\"_blank\">GPRO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299817-gopro-up-after-jpmorgan-dismisses-clips-concerns\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">GoPro up after JPMorgan dismisses Clips concerns</a></h4><ul><li>        GoPro (NASDAQ:<a href='https://seekingalpha.com/symbol/GPRO' title='GoPro'>GPRO</a>) shares are&nbsp;<font color='green'>up 2.48%</font>&nbsp;after JPMorgan <a href=\"https://www.cnbc.com/2017/10/06/gopro-shares-rise-after-jpmorgan-downplays-threat-from-googles-new-camera.html\" target=\"_blank\">dismisses</a> potential competition from the recently announced Google Clips camera.</li><li>               Analyst Paul Coster writes that Clips isn&rsquo;t designed as a point of view camera, isn&rsquo;t wearable in active settings, and lacks many other components of GoPro products including sound, image stabilization, and high frame-rate.&nbsp;</li><li>               Coster reiterates his Overweight rating on GoPro and $15 price target.&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3299370-gopro-shares-google-launch-event\" target=\"_blank\">GoPro shares down after Google launch event</a> (Oct. 4)</li></ul><div class=\"tiny-share-widget\" data-id=\"3299817\" data-linked=\"GoPro up after JPMorgan dismisses Clips concerns\" data-tweet=\"$GPRO - GoPro up after JPMorgan dismisses Clips concerns https://seekingalpha.com/news/3299817-gopro-up-after-jpmorgan-dismisses-clips-concerns?source=tweet\" data-url=\"https://seekingalpha.com/news/3299817-gopro-up-after-jpmorgan-dismisses-clips-concerns\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:42 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299861\" data-ts=\"1507314033\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VST\" target=\"_blank\">VST</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299861-vistra-energy-to-close-monticello-coal-plant-in-texas\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Vistra Energy to close Monticello coal plant in Texas</a></h4><ul><li>Vistra Energy (<a href='https://seekingalpha.com/symbol/VST' title='Vistra Energy Corp.'>VST</a> <font color='red'>-1.7%</font>) says it will <a href=\"http://www.chron.com/business/energy/article/Vistra-closing-mega-coal-plant-in-East-Texas-12258064.php\" target=\"_blank\">permanently shut</a> the 1,800 MW Monticello power plant, one of the largest coal-powered plants in Texas, in January 2018.</li><li>The plant, which opened more than 40 years ago, is  the latest in a string of coal plant closures in the U.S. as a glut of  cheap natural gas and advances in renewable energy  technology continue to depress wholesale power prices.</li><li>Coal plants in east Texas, which rely on an underground supply of  lignite, have long been targeted by environmentalists for their  contribution to the state's air pollution.</li></ul><div class=\"tiny-share-widget\" data-id=\"3299861\" data-linked=\"Vistra Energy to close Monticello coal plant in Texas\" data-tweet=\"$VST - Vistra Energy to close Monticello coal plant in Texas https://seekingalpha.com/news/3299861-vistra-energy-to-close-monticello-coal-plant-in-texas?source=tweet\" data-url=\"https://seekingalpha.com/news/3299861-vistra-energy-to-close-monticello-coal-plant-in-texas\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:20 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299815\" data-ts=\"1507312857\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299815-energy-materials-top-gainers-losers-of-2-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Energy/Materials - Top Gainers / Losers as of 2:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/GSM' title='Ferroglobe PLC'>GSM</a> <font color='green'>+10%</font>. <a href='https://seekingalpha.com/symbol/CHNR' title='China Natural Resources, Inc.'>CHNR</a> <font color='green'>+6%</font>. <a href='https://seekingalpha.com/symbol/NAK' title='Northern Dynasty Minerals Ltd'>NAK</a> <font color='green'>+6%</font>. <a href='https://seekingalpha.com/symbol/TGB' title='Taseko Mines Limited'>TGB</a> <font color='green'>+5%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/DELT' title='Delta Technology Holdings Limited'>DELT</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/ZN' title='Zion Oil & Gas Inc'>ZN</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/NE' title='Noble Corporation plc'>NE</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/IPI' title='Intrepid Potash, Inc.'>IPI</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/XCO' title='EXCO Resources, Inc.'>XCO</a> <font color='red'>-7%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3299815\" data-linked=\"Energy/Materials - Top Gainers / Losers as of 2:00 pm\" data-tweet=\"$GSM $CHNR $NAK - Energy/Materials - Top Gainers / Losers as of 2:00 pm https://seekingalpha.com/news/3299815-energy-materials-top-gainers-losers-of-2-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3299815-energy-materials-top-gainers-losers-of-2-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:00 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299813\" data-ts=\"1507312133\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299813-financials-top-5-gainers-losers-of-1-45-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Financials - Top 5 Gainers / Losers as of 1:45 PM</a></h4><ul><li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/JP' title='Jupai Holdings'>JP</a> <font color='green'>+13%</font>. <a href='https://seekingalpha.com/symbol/FANH' title='Fanhua Inc.'>FANH</a> <font color='green'>+5%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/RTNB' title='root9B Technologies, Inc.'>OTC:RTNB</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/PN' title='Patriot National, Inc.'>PN</a> <font color='red'>-8%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3299813\" data-linked=\"Financials - Top 5 Gainers / Losers as of 1:45 PM\" data-tweet=\"$JP $FANH $RTNB - Financials - Top 5 Gainers / Losers as of 1:45 PM https://seekingalpha.com/news/3299813-financials-top-5-gainers-losers-of-1-45-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3299813-financials-top-5-gainers-losers-of-1-45-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:48 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299812\" data-ts=\"1507311830\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KERX\" target=\"_blank\">KERX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299812-keryx-perks-up-ahead-of-fda-decision-on-expanded-use-of-auryxia-shares-ahead-7\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Keryx perks up ahead of FDA decision on expanded use of Auryxia; shares ahead 7%</a></h4><ul><li>Keryx Biopharmaceuticals (<a href='https://seekingalpha.com/symbol/KERX' title='Keryx Biopharmaceuticals, Inc.'>KERX</a> <font color='green'>+7%</font>) shows some life on double normal volume. No particular news accounts for the action but a key future event is the FDA's decision, expected no later than November 6, on the use of AURYXIA (ferric citrate) to treat iron deficiency anemia in patients with non-dialysis-dependent chronic kidney disease &#40;CKD&#41;.</li><li><a href=\"https://www.auryxia.com/\" target=\"_blank\">AURYXIA </a>is currently approved in the U.S. for the control of serum phosphorus levels in CKD patients on dialysis.</li><li>The expanded use, if approved, will greatly increase the potential market for the medication.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3249502-fda-review-keryx-bios-application-expanded-use-auryxia-shares-ahead-5-percent-premarket\" target=\"_blank\">FDA to review Keryx Bio's application for expanded use of Auryxia; shares ahead 5% premarket</a> (March 8)</li></ul><div class=\"tiny-share-widget\" data-id=\"3299812\" data-linked=\"Keryx perks up ahead of FDA decision on expanded use of Auryxia; shares ahead 7%\" data-tweet=\"$KERX - Keryx perks up ahead of FDA decision on expanded use of Auryxia; shares ahead 7% https://seekingalpha.com/news/3299812-keryx-perks-up-ahead-of-fda-decision-on-expanded-use-of-auryxia-shares-ahead-7?source=tweet\" data-url=\"https://seekingalpha.com/news/3299812-keryx-perks-up-ahead-of-fda-decision-on-expanded-use-of-auryxia-shares-ahead-7\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:43 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>25&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299809\" data-ts=\"1507310844\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HLF\" target=\"_blank\">HLF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299809-herbalife-to-purchase-6_7m-common-shares-68-under-self-tender-shares-ahead-10\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Herbalife to purchase 6.7M common shares at $68 under self-tender; shares ahead 10%</a></h4><ul><li>Herbalife (<a href='https://seekingalpha.com/symbol/HLF' title='Herbalife Ltd.'>HLF</a> <font color='green'>+10%</font>) <a href=\"https://seekingalpha.com/pr/16961931-herbalife-announces-preliminary-results-self-tender-offer\" target=\"_blank\">announces </a>that ~6.7M shares of stock have been tendered pursuant to its offer to buy up to $600M of its common shares for $60 - 68. It expects to accept ~6.7M shares at a cash purchase price of $68, representing a total cash cost of ~$457.8M exclusive of fees and expenses.</li><li>Sellers will receive one contingent value right &#40;CVR&#41; for each share sold that allows the holder to receive a contingent cash payment if the company is acquired in a go-private transaction within the next two years.</li><li>The share purchases will be funded by a $1.3B term loan under its $1.45B senior secured credit facility established in February.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3298924-herbalife-launches-self-tender-600m-common-stock-ups-q3-earnings-guidance\" target=\"_blank\">Herbalife launches self-tender for up to $600M of common stock; ups Q3 earnings guidance</a> (Oct. 3)</li></ul><div class=\"tiny-share-widget\" data-id=\"3299809\" data-linked=\"Herbalife to purchase 6.7M common shares at $68 under self-tender; shares ahead 10%\" data-tweet=\"$HLF - Herbalife to purchase 6.7M common shares at $68 under self-tender; shares ahead 10% https://seekingalpha.com/news/3299809-herbalife-to-purchase-6_7m-common-shares-68-under-self-tender-shares-ahead-10?source=tweet\" data-url=\"https://seekingalpha.com/news/3299809-herbalife-to-purchase-6_7m-common-shares-68-under-self-tender-shares-ahead-10\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:27 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>318&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299806\" data-ts=\"1507309264\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SLCA\" target=\"_blank\">SLCA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299806-u-s-silica-fairmount-santrol-merit-overweight-ratings-keybanc\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">U.S. Silica, Fairmount Santrol merit Overweight ratings at KeyBanc</a></h4><ul>     <li>U.S. Silica (<a href='https://seekingalpha.com/symbol/SLCA' title='U.S. Silica'>SLCA</a> <font color='red'>-4%</font>) and Fairmount Santrol (<a href='https://seekingalpha.com/symbol/FMSA' title='Fairmount Santrol, Inc.'>FMSA</a> <font color='red'>-4.1%</font>) are reinitiated with <a href=\"http://www.barrons.com/articles/fairmount-u-s-silica-not-just-pounding-sand-1507302023\" target=\"_blank\">Overweight ratings</a> at KeyBanc, which notes that frack sand names have been the worst performing oilfield service subsector YTD, down 27%.</li><li>KeyBanc believes it now sees compelling valuation entry points, as shares imply just 4.7X estimated 2018 EBITDA, at the lower end of its 4.5x-11x range of the past few years.</li><li>The firm expects tightness heading into year-end around highly demanded 40/70 sand that comprises 30% of SLCA&rsquo;s and 45% of FMSA&rsquo;s capacity given that shale plays use 45%-55% of 40/70 mesh in their completions.</li>          <li>On SLCA, the firm says the company's \"combination of attractive Northern White sand capacity and growth forays into in-basin Permian sand should allow for superior growth and attractive free cash generation in the coming  years.\"</li> </ul><div class=\"tiny-share-widget\" data-id=\"3299806\" data-linked=\"U.S. Silica, Fairmount Santrol merit Overweight ratings at KeyBanc\" data-tweet=\"$SLCA $SLCA $FMSA - U.S. Silica, Fairmount Santrol merit Overweight ratings at KeyBanc https://seekingalpha.com/news/3299806-u-s-silica-fairmount-santrol-merit-overweight-ratings-keybanc?source=tweet\" data-url=\"https://seekingalpha.com/news/3299806-u-s-silica-fairmount-santrol-merit-overweight-ratings-keybanc\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:01 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>26&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299803\" data-ts=\"1507308863\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMZN\" target=\"_blank\">AMZN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299803-general-electric-chooses-aws-preferred-cloud-provider\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">General Electric chooses AWS as preferred cloud provider</a></h4><ul><li>        Amazon (NASDAQ:<a href='https://seekingalpha.com/symbol/AMZN' title='Amazon.com, Inc.'>AMZN</a>) <a href=\"http://www.businesswire.com/news/home/20171005006368/en/General-Electric-Names-AWS-Preferred-Cloud-Provider\" target=\"_blank\">announces</a> that General Electric (NYSE:<a href='https://seekingalpha.com/symbol/GE' title='General Electric'>GE</a>) selected AWS as its preferred cloud provider.</li><li>                  GE began migration to AWS in 2014 with over 2K applications.    </li><li>               Amazon gets a little further ahead in the cloud infrastructure services market with every new partnership. In Q2, AWS accounted for 30.3% of the market with Microsoft coming in second at 13.8%, according to <a href=\"https://www.cnbc.com/2017/09/07/adobe-chooses-azure-as-its-preferred-cloud-for-sign.html\" target=\"_blank\">Canalys research</a>.&nbsp;</li><li>Amazon shares are&nbsp;<font color='green'>up 1.33%</font>.&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3299803\" data-linked=\"General Electric chooses AWS as preferred cloud provider\" data-tweet=\"$AMZN $AMZN $GE - General Electric chooses AWS as preferred cloud provider https://seekingalpha.com/news/3299803-general-electric-chooses-aws-preferred-cloud-provider?source=tweet\" data-url=\"https://seekingalpha.com/news/3299803-general-electric-chooses-aws-preferred-cloud-provider\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:54 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>26&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299802\" data-ts=\"1507308313\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299802-midday-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Midday Gainers / Losers</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/LINU-OLD' title='LiNiu Technology Group'>LINU-OLD</a> <font color='green'>+149%</font>. <a href='https://seekingalpha.com/symbol/SNCR' title='Synchronoss Technologies, Inc.'>SNCR</a> <font color='green'>+33%</font>. <a href='https://seekingalpha.com/symbol/OME' title='Omega Protein Corporation'>OME</a> <font color='green'>+33%</font>. <a href='https://seekingalpha.com/symbol/CNET' title='ChinaNet Online Holdings, Inc.'>CNET</a> <font color='green'>+28%</font>. <a href='https://seekingalpha.com/symbol/KONE' title='Kingtone Wirelessinfo Solution Holding Ltd'>KONE</a> <font color='green'>+27%</font>. <a href='https://seekingalpha.com/symbol/EHIC' title='eHi Car Services'>EHIC</a> <font color='green'>+20%</font>. <a href='https://seekingalpha.com/symbol/CCCL' title='China Ceramics Co., Ltd.'>CCCL</a> <font color='green'>+17%</font>. <a href='https://seekingalpha.com/symbol/CADC' title='China Advanced Construction Materials Group, Inc.'>CADC</a> <font color='green'>+17%</font>. <a href='https://seekingalpha.com/symbol/MTEM' title='Molecular Templates, Inc.'>MTEM</a> <font color='green'>+15%</font>. <a href='https://seekingalpha.com/symbol/INFI' title='Infinity Pharmaceuticals, Inc.'>INFI</a> <font color='green'>+14%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/NETE' title='Net Element International, Inc.'>NETE</a> <font color='red'>-14%</font>. <a href='https://seekingalpha.com/symbol/HVT' title='Haverty Furniture Companies Inc.'>HVT</a> <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/ALQA' title='Alliqua BioMedical, Inc.'>ALQA</a> <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/BNTC' title='Benitec'>BNTC</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/RGSE' title='RGS Energy, Inc.'>RGSE</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/XBIO' title='Xenetic Biosciences, Inc.'>XBIO</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/MRNS' title='Marinus Pharmaceuticals'>MRNS</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/RTNB' title='root9B Technologies, Inc.'>OTC:RTNB</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/LOV' title='Spark Networks, Inc'>LOV</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/DAR' title='Darling Ingredients Inc.'>DAR</a> <font color='red'>-9%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3299802\" data-linked=\"Midday Gainers / Losers\" data-tweet=\"$LINU-OLD $SNCR $OME - Midday Gainers / Losers https://seekingalpha.com/news/3299802-midday-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3299802-midday-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:45 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299795\" data-ts=\"1507306608\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CLZNF\" target=\"_blank\">CLZNF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299795-huntsman-slides-clariant-deal-doubts-rise\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Huntsman slides further as Clariant deal doubts rise</a></h4><ul>     <li>Activist investors seeking to block Clariant&rsquo;s merger (<a href='https://seekingalpha.com/symbol/CLZNF' title='Clariant AG'>OTCPK:CLZNF</a>, <a href='https://seekingalpha.com/symbol/CLZNY' title='Clariant AG ADR'>OTCPK:CLZNY</a>) with Huntsman (<a href='https://seekingalpha.com/symbol/HUN' title='Huntsman Corporation'>HUN</a> <font color='red'>-1.8%</font>) say they <a href=\"https://www.reuters.com/article/us-clariant-huntsman/white-tale-activists-increase-clariant-stake-finanz-und-wirtschaft-idUSKBN1CB1X1\" target=\"_blank\">own &ldquo;significantly more&rdquo; than 15%</a> of Clariant shares and are seeking to increase their stake, adding to the <a href=\"http://www.reuters.com/article/us-huntsman-m-a-clariant-investors-analy/doubts-growing-whether-clariant-can-seal-huntsman-deal-idUSKBN1CA1MU\" target=\"_blank\">growing doubts</a> that the merger ever will be completed.</li>     <li>White Tale Holdings became Clariant's largest shareholder last month with a disclosed 15.2% stake, and they say the proposed deal significantly undervalued Clariant and overvalued HUN.</li>     <li>Martin Lehmann, who manages the 3V Invest Swiss Small &amp; Mid Cap fund, says he does not expect the deal to go through at the proposed terms and that Clariant will be unable to win the necessary two thirds of shareholder votes.</li>     <li>White Tale, \"like us, see[s] limited strategic rationale in the deal and may be able to rally others against it, though it is likely to be approved by antitrust authorities with few hurdles,\" Berenberg analysts say.</li></ul><div class=\"tiny-share-widget\" data-id=\"3299795\" data-linked=\"Huntsman slides further as Clariant deal doubts rise\" data-tweet=\"$CLZNF $CLZNF $CLZNY - Huntsman slides further as Clariant deal doubts rise https://seekingalpha.com/news/3299795-huntsman-slides-clariant-deal-doubts-rise?source=tweet\" data-url=\"https://seekingalpha.com/news/3299795-huntsman-slides-clariant-deal-doubts-rise\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:16 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299792\" data-ts=\"1507305730\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299792-consumer-top-gainers-losers-of-12-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Consumer - Top Gainers / Losers as of 12:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/OME' title='Omega Protein Corporation'>OME</a> <font color='green'>+33%</font>. <a href='https://seekingalpha.com/symbol/CYRX' title='CryoPort, Inc.'>CYRX</a> <font color='green'>+13%</font>. <a href='https://seekingalpha.com/symbol/KBSF' title='KBS Fashion Group Limited'>KBSF</a> <font color='green'>+10%</font>. <a href='https://seekingalpha.com/symbol/KOSS' title='Koss Corporation'>KOSS</a> <font color='green'>+8%</font>. <a href='https://seekingalpha.com/symbol/OTIV' title='On Track Innovations Ltd'>OTIV</a> <font color='green'>+7%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/HELE' title='Helen of Troy Limited'>HELE</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/SAFM' title='Sanderson Farms, Inc.'>SAFM</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/NBEV' title='New Age Beverages Corporation'>NBEV</a> <font color='red'>-7%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3299792\" data-linked=\"Consumer - Top Gainers / Losers as of 12:00 pm\" data-tweet=\"$OME $CYRX $KBSF - Consumer - Top Gainers / Losers as of 12:00 pm https://seekingalpha.com/news/3299792-consumer-top-gainers-losers-of-12-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3299792-consumer-top-gainers-losers-of-12-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:02 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299789\" data-ts=\"1507304375\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TGT\" target=\"_blank\">TGT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299789-targetminus-3-after-costco-earnings\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Target -3% after Costco earnings</a></h4><ul> <li>Target (NYSE:<a href='https://seekingalpha.com/symbol/TGT' title='Target Corporation'>TGT</a>) is&nbsp;<font color='red'>down 2.60%</font>&nbsp;after Costco hits a stumbling block with renewal rates.</li> <li>Despite Costco's assertion that the decline was due to a credit card switch, it appears some anxious investors are taking it as a sign of further Amazon encroachment into retail.</li><li>Some traders are suggesting that the selling pressure today is overdone.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3299669-costco-minus-2_9-percent-despite-solid-comp-sales-q4-beat\" target=\"_blank\">Costco -2.9% despite solid comp sales, Q4 beat</a> (Oct. 5)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3299787-costco-drops-concerns-renewal-rates\" target=\"_blank\">Costco drops on concerns over renewal rates</a> (Oct. 6)</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3299789\" data-linked=\"Target -3% after Costco earnings\" data-tweet=\"$TGT - Target -3% after Costco earnings https://seekingalpha.com/news/3299789-targetminus-3-after-costco-earnings?source=tweet\" data-url=\"https://seekingalpha.com/news/3299789-targetminus-3-after-costco-earnings\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:39 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>14&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299773\" data-ts=\"1507301056\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CAMP\" target=\"_blank\">CAMP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299773-calamp-ceo-business-development-chief-sell-shares\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CalAmp CEO, business development chief sell shares</a></h4><ul>   <li>CalAmp (<a href=\"http://seekingalpha.com/symbol/CAMP\" target=\"_blank\">CAMP</a> <font color='red'>-1.5%</font>) SEC filings have indicated a pair of insider moves to sell the stock.</li>    <li>Senior VP of Business Development <a href=\"https://seekingalpha.com/filing/3721810\" target=\"_blank\">Garo Sarkissian</a> this week disposed of 4,994 shares at $24.03, and 4,839 shares at $23.75, to draw gross proceeds of $234,932.</li>    <li>Meanwhile, as part of an existing 10b5-1 trading plan, <a href=\"https://seekingalpha.com/filing/3721807#EDGAR_HTM_F1\" target=\"_blank\">President/CEO Michael Burdiek</a> filed that he exercised options for 4,000 shares at $2.13 each, sold 4,000 shares at $23.99 and another 5,000 shares at the same price.</li>    <li>The 9,000 shares sold brought Burdiek $215,910 in proceeds.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3299773\" data-linked=\"CalAmp CEO, business development chief sell shares\" data-tweet=\"$CAMP - CalAmp CEO, business development chief sell shares https://seekingalpha.com/news/3299773-calamp-ceo-business-development-chief-sell-shares?source=tweet\" data-url=\"https://seekingalpha.com/news/3299773-calamp-ceo-business-development-chief-sell-shares\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:44 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299771\" data-ts=\"1507300582\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MTEM\" target=\"_blank\">MTEM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299771-molecular-templates-continues-up-move-shares-ahead-14\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Molecular Templates continues up move, shares ahead 14%</a></h4><ul><li>Thinly traded micro cap Molecular Templates (<a href='https://seekingalpha.com/symbol/MTEM' title='Molecular Templates, Inc.'>MTEM</a> <font color='green'>+13.8%</font>) builds on its up move on almost six times normal volume, albeit on turnover of only 376K shares. The stock has rallied 70% since mid-August.</li><li>The company develops cancer therapies based on next-generation immunotoxins called Engineered Toxin Bodies. Its lead candidate is Phase 1/2-stage <a href=\"http://mtem.com/etb-platform/mt-3724/\" target=\"_blank\">MT-3724</a>, an immunotoxin targeting CD20,&nbsp;for B-cell malignancies.</li></ul><div class=\"tiny-share-widget\" data-id=\"3299771\" data-linked=\"Molecular Templates continues up move, shares ahead 14%\" data-tweet=\"$MTEM - Molecular Templates continues up move, shares ahead 14% https://seekingalpha.com/news/3299771-molecular-templates-continues-up-move-shares-ahead-14?source=tweet\" data-url=\"https://seekingalpha.com/news/3299771-molecular-templates-continues-up-move-shares-ahead-14\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:36 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299770\" data-ts=\"1507300045\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SWCH\" target=\"_blank\">SWCH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299770-switch-opens-first-day-up-28\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Switch opens first day up 28%</a></h4><ul><li>Switch (NYSE:<a href='https://seekingalpha.com/symbol/SWCH' title='Switch, Inc.'>SWCH</a>) opens its first day of trading at $21.70, up 27.6% on the $17 listing price.</li><li>Shares have continued to climb and are now&nbsp;<font color='green'>up 3.13%</font>&nbsp;from the open.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3299619-switch-goes-public-tomorrow-make-s-and-p-500\" target=\"_blank\">Switch goes public tomorrow but won't make the S&amp;P 500</a> (Oct. 5)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3299680-switch-prices-ipo-range-17-share\" target=\"_blank\">Switch prices IPO above range, at $17/share</a> (Oct. 5)</li></ul><div class=\"tiny-share-widget\" data-id=\"3299770\" data-linked=\"Switch opens first day up 28%\" data-tweet=\"$SWCH - Switch opens first day up 28% https://seekingalpha.com/news/3299770-switch-opens-first-day-up-28?source=tweet\" data-url=\"https://seekingalpha.com/news/3299770-switch-opens-first-day-up-28\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:27 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299768\" data-ts=\"1507299965\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EROS\" target=\"_blank\">EROS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299768-eros-internationalminus-2_6-q1-losses-in-line\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Eros International -2.6% with Q1 losses in line</a></h4><ul>   <li>Shares in Eros International (NYSE:<a href='https://seekingalpha.com/symbol/EROS' title='Eros International Plc'>EROS</a>) are <font color='red'>-2.6%</font> after some choppy morning trading following <a href=\"https://seekingalpha.com/news/3299727-eros-international-eps-line-beats-revenue\" target=\"_blank\">Q1 earnings</a> where it posted losses in line with expectations.</li>    <li>Revenues (of $60.8M) beat but were lower Y/Y, with a film slate of five compared to 14 films a year ago. Of the current quarter's films, one was high-budget, one medium and three low budget.</li>    <li>Theatrical revenues fell 37% to $23.6M; digital and ancillary revenues were up 40% to $19.8M.</li>    <li>Gross profits and operating profits were up (12% and 62.5% respectively) but EBITDA fell 12.7% to $15.8M.</li>    <li>Paying subscribers to streaming service Eros Now rose 27.6% Q/Q to 3.7M; registered users have grown to more than 75M.</li>    <li><a href=\"https://seekingalpha.com/article/4112071-eros-internationals-eros-ceo-jyoti-deshpande-q1-2018-results-earnings-call-transcript\" target=\"_blank\">Earnings call transcript</a></li>    <li><a href=\"https://seekingalpha.com/pr/16961761-eros-international-plc-reports-first-quarter-fiscal-year-2018-results\" target=\"_blank\">Press Release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3299768\" data-linked=\"Eros International -2.6% with Q1 losses in line\" data-tweet=\"$EROS - Eros International -2.6% with Q1 losses in line https://seekingalpha.com/news/3299768-eros-internationalminus-2_6-q1-losses-in-line?source=tweet\" data-url=\"https://seekingalpha.com/news/3299768-eros-internationalminus-2_6-q1-losses-in-line\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:26 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299767\" data-ts=\"1507299829\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BSTG\" target=\"_blank\">BSTG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299767-biostage-demoted-to-otcqb-effective-today-shares-down-65\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Biostage demoted to OTCQB effective today; shares down 65%</a></h4><ul><li>Nasdaq delisted Biostage (<a href='https://seekingalpha.com/symbol/BSTG' title='Biostage, Inc.'>OTC:BSTG</a>) from its small cap Capital Market today due to its inability to meet the minimum requirement for stockholders' equity. Shares will trade on the OTCQB starting today.</li><li>Shares are down&nbsp;<font color='red'>65%</font>&nbsp;on robust volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3299767\" data-linked=\"Biostage demoted to OTCQB effective today; shares down 65%\" data-tweet=\"$BSTG - Biostage demoted to OTCQB effective today; shares down 65% https://seekingalpha.com/news/3299767-biostage-demoted-to-otcqb-effective-today-shares-down-65?source=tweet\" data-url=\"https://seekingalpha.com/news/3299767-biostage-demoted-to-otcqb-effective-today-shares-down-65\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:23 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>16&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299766\" data-ts=\"1507299400\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ICPT\" target=\"_blank\">ICPT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299766-intercept-pharma-slips-9-on-fears-of-soft-ocaliva-script-volume\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Intercept Pharma slips 9% on fears of soft Ocaliva script volume</a></h4><ul><li>Intercept Pharmaceuticals (<a href='https://seekingalpha.com/symbol/ICPT' title='Intercept Pharmaceuticals'>ICPT</a> <font color='red'>-8.9%</font>) is down on modestly higher volume on investor concerns that prescription volume for Ocaliva (obeticholic acid) may be lower than expected following the recent news of deaths due to incorrect dosing.</li><li>Source: Bloomberg</li><li>Previously: <a href=\"https://seekingalpha.com/news/3297274-intercept-reports-ocaliva-related-deaths-certain-pbc-patients-due-failure-follow-recommended\" target=\"_blank\">Intercept reports that Ocaliva-related deaths in certain PBC patients due to failure to follow recommended dosing regimen; shares ahead 5% premarket</a> (Sept. 25)</li></ul><div class=\"tiny-share-widget\" data-id=\"3299766\" data-linked=\"Intercept Pharma slips 9% on fears of soft Ocaliva script volume\" data-tweet=\"$ICPT - Intercept Pharma slips 9% on fears of soft Ocaliva script volume https://seekingalpha.com/news/3299766-intercept-pharma-slips-9-on-fears-of-soft-ocaliva-script-volume?source=tweet\" data-url=\"https://seekingalpha.com/news/3299766-intercept-pharma-slips-9-on-fears-of-soft-ocaliva-script-volume\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:16 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>61&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299769\" data-ts=\"1507299135\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IMOS\" target=\"_blank\">IMOS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299769-chipmos-technologies-reports-q3-and-september-2017-revenue-sharesplus-7\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">ChipMOS Technologies reports Q3 and September 2017 revenue; shares +7%</a></h4><ul>     <li>ChipMOS Technologies (<a href='https://seekingalpha.com/symbol/IMOS' title='ChipMOS TECHNOLOGIES INC.'>IMOS</a> <font color='green'>+7.1%</font>) reports total revenue for the Q3, was NT$4.43B or US$146.1M, representing a decrease of 2.4% Q/Q, and a decrease of 7.1% Y/Y.</li>     <li>Revenue for the month of September 2017, was NT$1.53B or US$50.6M, an increase of 3.7% M/M and a decrease of 4.6% Y/Y.</li><li><a href=\"http://www.prnewswire.com/news-releases/chipmos-reports-september-2017-and-3q17-revenue-300532374.html\" target=\"_blank\">Press Release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3299769\" data-linked=\"ChipMOS Technologies reports Q3 and September 2017 revenue; shares +7%\" data-tweet=\"$IMOS - ChipMOS Technologies reports Q3 and September 2017 revenue; shares +7% https://seekingalpha.com/news/3299769-chipmos-technologies-reports-q3-and-september-2017-revenue-sharesplus-7?source=tweet\" data-url=\"https://seekingalpha.com/news/3299769-chipmos-technologies-reports-q3-and-september-2017-revenue-sharesplus-7\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:12 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299765\" data-ts=\"1507299112\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CRZO\" target=\"_blank\">CRZO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299765-carrizo-oil-gas-to-sell-marcellus-shale-assets-for-84m\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Carrizo Oil &amp; Gas to sell Marcellus Shale assets for $84M</a></h4><ul>     <li>Carrizo Oil &amp; Gas (<a href='https://seekingalpha.com/symbol/CRZO' title='Carrizo Oil & Gas, Inc.'>CRZO</a> <font color='red'>-1.9%</font>) <a href=\"https://seekingalpha.com/pr/16961709-carrizo-oil-and-gas-announces-sale-marcellus-shale-assets\" target=\"_blank\">agrees to sell</a> its assets in the Marcellus Shale to energy investment firm Kalnin Ventures for $84M.</li>     <li>CRZO says it also could receive up to $7.5M in contingent payments in total, based on natural gas prices exceeding certain thresholds over the next three years.</li>     <li>Net production from the assets averaged more than 40M cf/day of natural gas over the first nine months of 2017.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3299765\" data-linked=\"Carrizo Oil &amp; Gas to sell Marcellus Shale assets for $84M\" data-tweet=\"$CRZO - Carrizo Oil &amp; Gas to sell Marcellus Shale assets for $84M https://seekingalpha.com/news/3299765-carrizo-oil-gas-to-sell-marcellus-shale-assets-for-84m?source=tweet\" data-url=\"https://seekingalpha.com/news/3299765-carrizo-oil-gas-to-sell-marcellus-shale-assets-for-84m\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:11 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299762\" data-ts=\"1507298700\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ALQA\" target=\"_blank\">ALQA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299762-alliqua-bios-1-10-reverse-split-effective-today-shares-off-10\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Alliqua Bio&#39;s 1:10 reverse split effective today; shares off 10%</a></h4><ul><li>Post-split trading <a href=\"https://seekingalpha.com/pr/16961381-alliqua-biomedical-inc-announces-1minus-10-reverse-stock-split\" target=\"_blank\">commences today</a> after Alliqua BioMedical's (<a href='https://seekingalpha.com/symbol/ALQA' title='Alliqua BioMedical, Inc.'>ALQA</a> <font color='red'>-9.9%</font>) 1:10 reverse split of its common stock that was approved by shareholders on September 13 and the board on October 2.</li></ul><div class=\"tiny-share-widget\" data-id=\"3299762\" data-linked=\"Alliqua Bio&#39;s 1:10 reverse split effective today; shares off 10%\" data-tweet=\"$ALQA $ADYX - Alliqua Bio&#39;s 1:10 reverse split effective today; shares off 10% https://seekingalpha.com/news/3299762-alliqua-bios-1-10-reverse-split-effective-today-shares-off-10?source=tweet\" data-url=\"https://seekingalpha.com/news/3299762-alliqua-bios-1-10-reverse-split-effective-today-shares-off-10\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:05 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299758\" data-ts=\"1507297902\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CAPR\" target=\"_blank\">CAPR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299758-capricor-to-employ-peripheral-iv-administration-of-cell-therapy-capminus-1002-in-mid-stage\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Capricor to employ peripheral IV administration of cell therapy CAP-1002 in mid-stage DMD study; shares ahead 13%</a></h4><ul><li>Capricor Therapeutics (<a href='https://seekingalpha.com/symbol/CAPR' title='Capricor Therapeutics, Inc.'>CAPR</a> <font color='green'>+12.8%</font>) plans to administer CAP-1002 intravenously in its upcoming Phase 2 clinical trial, HOPE-2, in boys and young men with Duchenne muscular dystrophy &#40;DMD&#41;.</li><li>In a <a href=\"https://seekingalpha.com/pr/16961892-capricor-therapeutics-reports-intravenous-administration-capminus-1002-shown-effective\" target=\"_blank\">poster presentation</a> at the Alliance for Regenerative Medicine's Cell and Gene Therapy Meeting on the Mesa, researchers from the company and Cedars-Sinai Medical Center reported encouraging preclinical data that showed IV administration of cardiosphere-derived cells (CDCs) increased exercise capacity and diaphragm function. The results also showed that CDCs predominantly distribute to the lungs after injection and are cleared within three weeks. Dosing at more than 2.5x the human equivalent dose for HOPE-2 was observed to be safe.</li><li>Enrollment in HOPE-2 should commence in Q1 2018.</li><li>The previous method of administering CAP-1002 was infusion directly into the patient's coronary artery via a catheter.</li></ul><div class=\"tiny-share-widget\" data-id=\"3299758\" data-linked=\"Capricor to employ peripheral IV administration of cell therapy CAP-1002 in mid-stage DMD study; shares ahead 13%\" data-tweet=\"$CAPR - Capricor to employ peripheral IV administration of cell therapy CAP-1002 in mid-stage DMD study; shares ahead 13% https://seekingalpha.com/news/3299758-capricor-to-employ-peripheral-iv-administration-of-cell-therapy-capminus-1002-in-mid-stage?source=tweet\" data-url=\"https://seekingalpha.com/news/3299758-capricor-to-employ-peripheral-iv-administration-of-cell-therapy-capminus-1002-in-mid-stage\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:51 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299755\" data-ts=\"1507296418\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GIMO\" target=\"_blank\">GIMO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299755-gigamonminus-5_9-on-report-elliott-takeout-bid-stalls\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Gigamon -5.9% on report that Elliott takeout bid stalls</a></h4><ul>   <li>Gigamon (NYSE:<a href='https://seekingalpha.com/symbol/GIMO' title='Gigamon, Inc.'>GIMO</a>) is<font color='red'> 5.9% lower</font> premarket after a report that a <a href=\"https://seekingalpha.com/news/3294701-gigamon-leaps-reported-purchase-offer-elliotts-evergreen\" target=\"_blank\">takeout bid</a> from an affiliate of Elliott Management has <a href=\"https://www.reuters.com/article/us-gigamon-m-a-elliott/elliotts-gigamon-bid-stalls-amid-price-disagreements-sources-idUSKBN1CB01I\" target=\"_blank\">stalled out over price issues</a>.</li>    <li>The bid from Evergreen (Elliott's private-equity arm) has \"ground to a halt,\" Reuters says, as the $1.6B Gigamon rejected an offer that came in below the company's share price.</li>    <li>Negotiations could pick back up with Elliott or Gigamon could get an offer from another party, the report says.</li>    <li>Elliott disclosed a 15.3% stake in Gigamon in May, making it one of the company's biggest shareholders.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3299755\" data-linked=\"Gigamon -5.9% on report that Elliott takeout bid stalls\" data-tweet=\"$GIMO - Gigamon -5.9% on report that Elliott takeout bid stalls https://seekingalpha.com/news/3299755-gigamonminus-5_9-on-report-elliott-takeout-bid-stalls?source=tweet\" data-url=\"https://seekingalpha.com/news/3299755-gigamonminus-5_9-on-report-elliott-takeout-bid-stalls\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:26 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299752\" data-ts=\"1507296023\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TRPX\" target=\"_blank\">TRPX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299752-therapix-inks-deal-catalent-to-develop-and-manufacture-lead-candidate-thx-ts01-shares-ahead-2\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Therapix inks deal with Catalent to develop and manufacture lead candidate THX-TS01; shares ahead 2% premarket</a></h4><ul><li>Thinly traded nano cap Therapix Biosciences (NASDAQ:<a href='https://seekingalpha.com/symbol/TRPX' title='Therapix Biosciences'>TRPX</a>) is up&nbsp;<font color='green'>2%</font>&nbsp;premarket in response to its <a href=\"https://seekingalpha.com/pr/16961840-therapix-signs-formulation-development-clinical-manufacturing-agreement-catalent-thx-ts01\" target=\"_blank\">announcement </a>of an exclusive agreement with Catalent Pharma Solutions (NYSE:<a href='https://seekingalpha.com/symbol/CTLT' title='Catalent'>CTLT</a>) to formulate, develop and manufacture THX-TS01, its candidate for the treatment of Tourette syndrome.</li><li>Catalent will develop THX-TS01 in a GMP-compliant softgel formulation for use in clinical trials and commercialization, once approved.</li></ul><div class=\"tiny-share-widget\" data-id=\"3299752\" data-linked=\"Therapix inks deal with Catalent to develop and manufacture lead candidate THX-TS01; shares ahead 2% premarket\" data-tweet=\"$TRPX $TRPX $CTLT - Therapix inks deal with Catalent to develop and manufacture lead candidate THX-TS01; shares ahead 2% premarket https://seekingalpha.com/news/3299752-therapix-inks-deal-catalent-to-develop-and-manufacture-lead-candidate-thx-ts01-shares-ahead-2?source=tweet\" data-url=\"https://seekingalpha.com/news/3299752-therapix-inks-deal-catalent-to-develop-and-manufacture-lead-candidate-thx-ts01-shares-ahead-2\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:20 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299751\" data-ts=\"1507295892\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299751-premarket-gainers-of-9-05\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Gainers as of 9:05 am</a></h4><ul>     <li><a href='https://seekingalpha.com/symbol/OME' title='Omega Protein Corporation'>OME</a> <font color='green'>+32%</font>&nbsp;on being <a href=\"https://seekingalpha.com/news/3299701-omega-protein-corporation-acquired-cooke-inc-22_00-per-share\" target=\"_blank\">acquired</a> by Cooke for $22.00/share.</li>     <li><a href='https://seekingalpha.com/symbol/SNCR' title='Synchronoss Technologies, Inc.'>SNCR</a> <font color='green'>+27%&nbsp;</font>on resuming strategic alternative talks with Siris.</li>     <li><a href='https://seekingalpha.com/symbol/XXII' title='22nd Century Group, Inc.'>XXII</a> <font color='green'>+16%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3299737-22nd-century-group-15-percent-premarket-results-late-stage-study-confirming-advantages-low\" target=\"_blank\">results</a> from late-stage study confirming advantages of very low nicotine cigarettes.</li>     <li><a href='https://seekingalpha.com/symbol/KTOV' title='Kitov Pharma Ltd.'>KTOV</a> <font color='green'>+13%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3299750-kitov-ups-stake-oncology-focused-tyrnovo-92-percent-shares-ahead-9-percent-premarket\" target=\"_blank\">raising</a> stake in oncology-focused TyrNovo to 92%.</li>     <li><a href='https://seekingalpha.com/symbol/CAPR' title='Capricor Therapeutics, Inc.'>CAPR</a> <font color='green'>+8%</font>&nbsp;on <a href=\"https://seekingalpha.com/pr/16961892-capricor-therapeutics-reports-intravenous-administration-capminus-1002-shown-effective\" target=\"_blank\">reports</a> of intravenous administration of CAP-1002 shown to be effective in preclinical models of duchenne muscular dystrophy.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3299751\" data-linked=\"Premarket Gainers as of 9:05 am\" data-tweet=\"$OME $SNCR $XXII - Premarket Gainers as of 9:05 am https://seekingalpha.com/news/3299751-premarket-gainers-of-9-05?source=tweet\" data-url=\"https://seekingalpha.com/news/3299751-premarket-gainers-of-9-05\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:18 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299750\" data-ts=\"1507295538\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KTOV\" target=\"_blank\">KTOV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299750-kitov-ups-stake-in-oncology-focused-tyrnovo-to-92-shares-ahead-9-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Kitov ups stake in oncology-focused TyrNovo to 92%; shares ahead 9% premarket</a></h4><ul><li>Thinly traded nano cap Kitov Pharmaceuticals Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/KTOV' title='Kitov Pharma Ltd.'>KTOV</a>) is up&nbsp;<font color='green'>9%&nbsp;</font>premarket on increased volume on the heels of its <a href=\"https://seekingalpha.com/pr/16961822-kitov-boosts-ownership-tyrnovo-oncology-platform-exchange-shares-stock\" target=\"_blank\">announcement </a>that it has acquired an additional 27% stake in privately held TyrNovo, a developer of small molecule oncology drugs. Its stake is now ~92%.</li><li>In this latest transaction with a group of minority shareholders, Kitov issued 13,169,689 new ordinary shares (equivalent to 658,484 American Depositary Shares) at $2.50 per ADS based on a mutually agreed $7M valuation of TyrNovo.</li><li>Kitov says TyrNovo's lead candidate NT219 has shown encouraging preclinical efficacy in treatment-resistant tumors when combined with Merck's Keytruda (pembrolizumab).</li></ul><div class=\"tiny-share-widget\" data-id=\"3299750\" data-linked=\"Kitov ups stake in oncology-focused TyrNovo to 92%; shares ahead 9% premarket\" data-tweet=\"$KTOV - Kitov ups stake in oncology-focused TyrNovo to 92%; shares ahead 9% premarket https://seekingalpha.com/news/3299750-kitov-ups-stake-in-oncology-focused-tyrnovo-to-92-shares-ahead-9-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3299750-kitov-ups-stake-in-oncology-focused-tyrnovo-to-92-shares-ahead-9-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:12 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299747\" data-ts=\"1507295321\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299747-premarket-losers-of-9-05\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Losers as of 9:05 am</a></h4><ul>     <li>ITEK <font color='red'>-8%</font>.</li><li><a href='https://seekingalpha.com/symbol/GIMO' title='Gigamon, Inc.'>GIMO</a> <font color='red'>-6%</font>.</li><li><a href='https://seekingalpha.com/symbol/IMGN' title='ImmunoGen, Inc.'>IMGN</a>&nbsp;<font color='red'>-5%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3299696-immunogen-prices-14_5m-shares-common-stock-offering-6_50-shares-2-percent-premarket\" target=\"_blank\">pricing</a> 14.5M shares of common stock.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3299747\" data-linked=\"Premarket Losers as of 9:05 am\" data-tweet=\"$RCKT $GIMO $IMGN - Premarket Losers as of 9:05 am https://seekingalpha.com/news/3299747-premarket-losers-of-9-05?source=tweet\" data-url=\"https://seekingalpha.com/news/3299747-premarket-losers-of-9-05\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:08 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299741\" data-ts=\"1507294660\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ELGX\" target=\"_blank\">ELGX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299741-endologix-on-go-to-launch-study-of-nellix-evas-for-infrarenal-abdominal-aortic-aneurysms\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Endologix on go to launch study of Nellix EVAS for infrarenal abdominal aortic aneurysms; shares ahead 5% premarket</a></h4><ul><li>Endologix (NASDAQ:<a href='https://seekingalpha.com/symbol/ELGX' title='Endologix Inc'>ELGX</a>) is up<font color='green'> 5%</font>&nbsp;premarket on light volume in response to its <a href=\"https://seekingalpha.com/pr/16961792-endologix-receives-ide-approval-evas2-confirmatory-clinical-study-evaluate-nellix\" target=\"_blank\">announcement </a>that the FDA has signed off on its IDE clearing the way for a 90-subject confirmatory study, EVAS2, evaluating the Nellix EndoVascular Aneurysm Sealing System &#40;EVAS&#41; for the treatment of infrarenal abdominal aortic aneurysms.</li><li>The company says it expects to earn U.S. approval for the indication by 2020.</li></ul><div class=\"tiny-share-widget\" data-id=\"3299741\" data-linked=\"Endologix on go to launch study of Nellix EVAS for infrarenal abdominal aortic aneurysms; shares ahead 5% premarket\" data-tweet=\"$ELGX - Endologix on go to launch study of Nellix EVAS for infrarenal abdominal aortic aneurysms; shares ahead 5% premarket https://seekingalpha.com/news/3299741-endologix-on-go-to-launch-study-of-nellix-evas-for-infrarenal-abdominal-aortic-aneurysms?source=tweet\" data-url=\"https://seekingalpha.com/news/3299741-endologix-on-go-to-launch-study-of-nellix-evas-for-infrarenal-abdominal-aortic-aneurysms\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:57 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299737\" data-ts=\"1507293700\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/XXII\" target=\"_blank\">XXII</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299737-22nd-century-group-up-15-premarket-on-results-from-late-stage-study-confirming-advantages-of\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">22nd Century Group up 15% premarket on results from late-stage study confirming advantages of very low nicotine cigarettes</a></h4><ul><li>22nd Century Group (NYSEMKT:<a href='https://seekingalpha.com/symbol/XXII' title='22nd Century Group, Inc.'>XXII</a>) is up&nbsp;<font color='green'>15%</font>&nbsp;premarket on robust volume in response its <a href=\"https://seekingalpha.com/pr/16961705-phase-iii-study-using-22nd-century-s-spectrum-research-cigarettes-demonstrates-immediate\" target=\"_blank\">announcement </a>of positive results from a 1,250-subject, 20-week study investigating the cessation behavior of smokers who used very low nicotine cigarettes compared to normal nicotine cigarettes. The basic findings were revealed at the 5th Annual Conference on Tobacco Regulatory Science in Burlington, VT.</li><li>Study participants were assigned to one of three arms: immediate reduction to very low nicotine cigarettes, gradual reduction in reduced nicotine cigarettes or normal nicotine cigarettes. The aim was to determine which approach produced the best cessation outcome.</li><li>In a panel presentation, lead investigator Dr. Dorothy Hatsukami said an immediate reduction in nicotine is \"most likely to lead to less harm'\" adding that compensatory smoking (smoking more low nicotine cigarettes to ingest the same of nicotine in normal cigarettes) is less likely to occur with an immediate reduction in nicotine and there was a \"greater likelihood of more rapid smoking cessation\" with the immediate approach.</li><li>22nd Century says it is the only company in the world capable of growing tobacco with nicotine levels of 0.4 mg/gm, 95% lower than conventional cigarettes. It provided its very low nicotine SPECTRUM research cigarettes for the study.</li><li>Related tickers: <a href='https://seekingalpha.com/symbol/MO' title='Altria Group, Inc.'>MO</a> <a href='https://seekingalpha.com/symbol/PM' title='Philip Morris International Inc.'>PM</a> <a href='https://seekingalpha.com/symbol/BTI' title='British American Tobacco p.l.c. &#40;American Depository Receipts&#41;'>BTI</a> <a href='https://seekingalpha.com/symbol/RAI' title='Reynolds American, Inc.'>RAI</a> <a href='https://seekingalpha.com/symbol/TPB' title='Turning Point Brands'>TPB</a> <a href='https://seekingalpha.com/symbol/VGR' title='Vector Group Ltd.'>VGR</a> <a href='https://seekingalpha.com/symbol/GLLA' title='Gilla, Inc.'>OTCPK:GLLA</a> <a href='https://seekingalpha.com/symbol/IMBBY' title='Imperial Brands PLC ADR'>OTCQX:IMBBY</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3299737\" data-linked=\"22nd Century Group up 15% premarket on results from late-stage study confirming advantages of very low nicotine cigarettes\" data-tweet=\"$XXII $XXII $MO - 22nd Century Group up 15% premarket on results from late-stage study confirming advantages of very low nicotine cigarettes https://seekingalpha.com/news/3299737-22nd-century-group-up-15-premarket-on-results-from-late-stage-study-confirming-advantages-of?source=tweet\" data-url=\"https://seekingalpha.com/news/3299737-22nd-century-group-up-15-premarket-on-results-from-late-stage-study-confirming-advantages-of\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:41 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>93&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299730\" data-ts=\"1507291957\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ALB\" target=\"_blank\">ALB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299730-albemarleminus-2_5-goldman-cuts-to-neutral-from-conviction-buy\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Albemarle -2.5% as Goldman cuts to Neutral from Conviction Buy</a></h4><ul>     <li>Albemarle (NYSE:<a href='https://seekingalpha.com/symbol/ALB' title='Albemarle Corporation'>ALB</a>) <font color='red'>-2.5%</font> premarket after Goldman Sachs <a href=\"http://thefly.com/thestreet/realmoney/index.php/ALBid2619338/ALB-Albemarle-downgraded-to-Neutral-from-Conviction-Buy-at-Goldman-Sachs\" target=\"_blank\">downgrades</a> shares to Neutral from Conviction Buy after shares have surged 62% YTD.</li>     <li>Goldman says ALB has transformed from a value-oriented chemical stock into a \"thematic  growth engine\" over the past two years as investors shifted their focus to the potential of an electric vehicle revolution.</li><li>The firm believes the stock's upside is priced in close to its $142 price target, but the lithium market should remain tight through the end of the decade.</li></ul><div class=\"tiny-share-widget\" data-id=\"3299730\" data-linked=\"Albemarle -2.5% as Goldman cuts to Neutral from Conviction Buy\" data-tweet=\"$ALB - Albemarle -2.5% as Goldman cuts to Neutral from Conviction Buy https://seekingalpha.com/news/3299730-albemarleminus-2_5-goldman-cuts-to-neutral-from-conviction-buy?source=tweet\" data-url=\"https://seekingalpha.com/news/3299730-albemarleminus-2_5-goldman-cuts-to-neutral-from-conviction-buy\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:12 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>26&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299725\" data-ts=\"1507291929\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AVEO\" target=\"_blank\">AVEO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299725-aveos-late-stage-study-comparing-tivozanib-to-sorafenib-in-rcc-to-continue-planned-shares\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">AVEO&#39;s late-stage study comparing tivozanib to sorafenib in RCC to continue as planned; shares ahead 4% premarket</a></h4><ul><li>AVEO Oncology (NASDAQ:<a href='https://seekingalpha.com/symbol/AVEO' title='AVEO Pharmaceuticals, Inc.'>AVEO</a>) is up&nbsp;<font color='green'>4%</font>&nbsp;premarket on modest volume on the heels of its <a href=\"https://seekingalpha.com/pr/16961550-aveo-oncology-announces-completion-tivominus-3-study-futility-analysis-changes-study-protocol\" target=\"_blank\">announcement </a>that the Phase 3 clinical trial, TIVO-3, comparing FOTIVDA (tivozanib) to Bayer's (<a href='https://seekingalpha.com/symbol/BAYRY' title='Bayer A.G. ADR'>OTCPK:BAYRY</a>) NEXAVAR (sorafenib) in patients with refractory advanced renal cell carcinoma &#40;RCC&#41; will continue as planned. The action was based on the outcome of a preplanned futility analysis that was reviewed by an independent statistician.</li><li>Topline data should be available in Q1 2018.</li><li>Results from TIVO-3 and previously completed TIVO-1 will support U.S. marketing applications for first- and third-line RCC.</li></ul><div class=\"tiny-share-widget\" data-id=\"3299725\" data-linked=\"AVEO&#39;s late-stage study comparing tivozanib to sorafenib in RCC to continue as planned; shares ahead 4% premarket\" data-tweet=\"$AVEO $AVEO $BAYRY - AVEO&#39;s late-stage study comparing tivozanib to sorafenib in RCC to continue as planned; shares ahead 4% premarket https://seekingalpha.com/news/3299725-aveos-late-stage-study-comparing-tivozanib-to-sorafenib-in-rcc-to-continue-planned-shares?source=tweet\" data-url=\"https://seekingalpha.com/news/3299725-aveos-late-stage-study-comparing-tivozanib-to-sorafenib-in-rcc-to-continue-planned-shares\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:12 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299720\" data-ts=\"1507291043\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TSM\" target=\"_blank\">TSM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299720-tsmc-reports-lower-september-revenues\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">TSMC reports lower September revenues</a></h4><ul><li>           Taiwan Semiconductor Manufacturing Company (NYSE:<a href='https://seekingalpha.com/symbol/TSM' title='Taiwan Semiconductor Manufacturing Company Ltd.'>TSM</a>) <a href=\"http://www.digitimes.com/news/a20171006VL200.html\" target=\"_blank\">reports</a> September revenues of $2.92B, down 1.3% on the year and down 3.6% on the month. </li><li> YTD revenues total $23.1B, up 2.1% on the year.&nbsp; </li><li>           Taiwan Semiconductor shares are&nbsp;<font color='green'>up 0.91%</font>&nbsp;premarket.&nbsp; </li><li>    Previously: <a href=\"https://seekingalpha.com/news/3298602-tsmc-founder-chairman-retire-june\" target=\"_blank\">TSMC founder and chairman to retire in June</a> (Oct. 2)</li></ul><div class=\"tiny-share-widget\" data-id=\"3299720\" data-linked=\"TSMC reports lower September revenues\" data-tweet=\"$TSM - TSMC reports lower September revenues https://seekingalpha.com/news/3299720-tsmc-reports-lower-september-revenues?source=tweet\" data-url=\"https://seekingalpha.com/news/3299720-tsmc-reports-lower-september-revenues\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:57 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299715\" data-ts=\"1507289556\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TROV\" target=\"_blank\">TROV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299715-trovagenes-pcmminus-075-orphan-drug-for-aml-shares-ahead-23-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Trovagene&#39;s PCM-075 an Orphan Drug for AML; shares ahead 23% premarket</a></h4><ul><li>Thinly traded nano cap Trovagene (NASDAQ:<a href='https://seekingalpha.com/symbol/TROV' title='TrovaGene, Inc.'>TROV</a>) is up&nbsp;<font color='green'>23%</font>&nbsp;premarket on average volume in response to the FDA's Orphan Drug <a href=\"https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=602617\" target=\"_blank\">designation </a>of PMC-075 for acute myeloid leukemia &#40;AML&#41;.</li><li>Among the benefits of Orphan Drug status in the U.S. is a seven-year period of market exclusivity for the indication, if approved.</li></ul><div class=\"tiny-share-widget\" data-id=\"3299715\" data-linked=\"Trovagene&#39;s PCM-075 an Orphan Drug for AML; shares ahead 23% premarket\" data-tweet=\"$TROV - Trovagene&#39;s PCM-075 an Orphan Drug for AML; shares ahead 23% premarket https://seekingalpha.com/news/3299715-trovagenes-pcmminus-075-orphan-drug-for-aml-shares-ahead-23-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3299715-trovagenes-pcmminus-075-orphan-drug-for-aml-shares-ahead-23-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:32 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299710\" data-ts=\"1507288613\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NVAX\" target=\"_blank\">NVAX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299710-premarket-analyst-action-healthcare\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket analyst action - healthcare</a></h4><ul><li>Novavax (NASDAQ:<a href='https://seekingalpha.com/symbol/NVAX' title='Novavax, Inc.'>NVAX</a>) initiated with Neutral rating by Seaport Global Securities.</li><li>Seaport initiates coverage of the following with Buy ratings: Aurinia Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/AUPH' title='Aurinia Pharmaceuticals Inc.'>AUPH</a>), Pluristem Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/PSTI' title='Pluristem Therapeutics, Inc.'>PSTI</a>), Conatus Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/CNAT' title='Conatus Pharmaceuticals'>CNAT</a>), AVEO Oncology (NASDAQ:<a href='https://seekingalpha.com/symbol/AVEO' title='AVEO Pharmaceuticals, Inc.'>AVEO</a>), Cytokinetics (NASDAQ:<a href='https://seekingalpha.com/symbol/CYTK' title='Cytokinetics, Incorporated'>CYTK</a>), Evoke Pharma (NASDAQ:<a href='https://seekingalpha.com/symbol/EVOK' title='Evoke Pharma, Inc.'>EVOK</a>); Galectin Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/GALT' title='Galectin Therapeutics, Inc.'>GALT</a>), Galmed Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/GLMD' title='Galmed Pharmaceuticals Ltd.'>GLMD</a>), Intercept Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/ICPT' title='Intercept Pharmaceuticals'>ICPT</a>), Seres Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/MCRB' title='Seres Therapeutics'>MCRB</a>), Rexahn Pharmaceuticals (NYSEMKT:<a href='https://seekingalpha.com/symbol/RNN' title='Rexahn Pharmaceuticals Inc'>RNN</a>).</li><li>RedHill Biopharma (NASDAQ:<a href='https://seekingalpha.com/symbol/RDHL' title='RedHill Biopharma Ltd.'>RDHL</a>) initiated with Buy rating and $19 (90% upside) price target by Seaport.</li><li>Cogentix Medical (NASDAQ:<a href='https://seekingalpha.com/symbol/CGNT' title='Cogentix Medical, Inc.'>CGNT</a>) initiated with Outperform rating and $5 (75% upside) price target by JMP Securities.</li><li>Abbott (NYSE:<a href='https://seekingalpha.com/symbol/ABT' title='Abbott Laboratories'>ABT</a>) resumed with Neutral rating by JPMorgan.</li><li>Walgreens Boots Alliance (NASDAQ:<a href='https://seekingalpha.com/symbol/WBA' title='Walgreens Boots Alliance, Inc.'>WBA</a>) downgraded to Equal Weight by Morgan Stanley.</li></ul><div class=\"tiny-share-widget\" data-id=\"3299710\" data-linked=\"Premarket analyst action - healthcare\" data-tweet=\"$NVAX $NVAX $AUPH - Premarket analyst action - healthcare https://seekingalpha.com/news/3299710-premarket-analyst-action-healthcare?source=tweet\" data-url=\"https://seekingalpha.com/news/3299710-premarket-analyst-action-healthcare\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:16 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>21&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3299696\" data-ts=\"1507284953\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IMGN\" target=\"_blank\">IMGN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3299696-immunogen-prices-14_5m-shares-of-common-stock-offering-6_50-shares-off-2-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">ImmunoGen prices 14.5M shares of common stock offering at $6.50; shares off 2% premarket</a></h4><ul> <li>ImmunoGen (NASDAQ:<a href='https://seekingalpha.com/symbol/IMGN' title='ImmunoGen, Inc.'>IMGN</a>) <a href=\"https://seekingalpha.com/pr/16961625-immunogen-announces-pricing-public-offering-common-stock\" target=\"_blank\">prices</a> public offering of 14.5M shares of its common stock at       a price of $6.50 per share for the expected gross proceeds of ~$94.3M.</li><li>Underwriters are granted a 30-day option to purchase up to       an additional 2,175,000 shares.</li>          <li>Net proceeds together       with its existing capital will be used to fund its operations, R&amp;D activities, clinical trial       activities, for commercialization &amp; acquisitions of new       technologies, capital expenditures and working capital.</li><li>Shares are down&nbsp;<font color='red'>2%</font>&nbsp;premarket on light volume. Yesterday's close was $7.03.</li>     </ul><div class=\"tiny-share-widget\" data-id=\"3299696\" data-linked=\"ImmunoGen prices 14.5M shares of common stock offering at $6.50; shares off 2% premarket\" data-tweet=\"$IMGN - ImmunoGen prices 14.5M shares of common stock offering at $6.50; shares off 2% premarket https://seekingalpha.com/news/3299696-immunogen-prices-14_5m-shares-of-common-stock-offering-6_50-shares-off-2-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3299696-immunogen-prices-14_5m-shares-of-common-stock-offering-6_50-shares-off-2-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:15 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li>","count":45,"message":null,"success":true,"today":{"start":1577077200,"end":1577163599,"str":"Monday, December 23, 2019"},"yesterday":{"start":1576990800,"end":1577077199}}